Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of ABI-H2158 with CYP3A4 Modulators, pH Modifiers, and Oral Contraceptives
NCT04142762Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of firzacorvir in Chronic Hepatitis B (CHB) (5 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Area under the plasma concentration time curve of ABI-H2158 at Day 17, Maximum observed plasma concentration of ABI-H2158 at Day 17 and 4 more. Started Oct 2019; status: completed.
02
Drugs
firzacorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04142762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142762.